Gemini Therapeutics, Inc. (GMTX)

NASDAQ: GMTX · IEX Real-Time Price · USD
1.76
-0.17 (-8.81%)
Aug 12, 2022 4:00 PM EDT - Market closed

Income Statement (Annual)

Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year 202120202019
Selling, General & Admin
20.295.876.75
Research & Development
48.7228.1734.47
Operating Expenses
6934.0441.23
Operating Income
-69-34.04-41.23
Interest Expense / Income
2.166.830.35
Other Expense / Income
0.71-0.03-0.18
Pretax Income
-71.87-40.84-41.4
Net Income
-71.87-40.84-41.4
Net Income Common
-71.87-40.84-41.4
Shares Outstanding (Basic)
40155
Shares Outstanding (Diluted)
40155
Shares Change
167.03%192.28%-
EPS (Basic)
-1.78-2.70-8.01
EPS (Diluted)
-1.78-2.70-8.01
Free Cash Flow Per Share
-1.47-2.17-7.50
EBITDA
-69.48-33.69-40.76
Depreciation & Amortization
0.230.320.29
EBIT
-69.71-34.01-41.05
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).